NewsfeedFollowed Companies

Ionis's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Ionis is a drug discovery company that engages in the development and commercialization of ribonucleic acid-targeted the... Read more

Based on data from Ionis's latest SEC filings

Annual Revenue

Based on data from Ionis's latest SEC filings

Employees

Stanley T. Crooke's photo - Chairman & CEO of Ionis

Chairman & CEO

Stanley T. Crooke

CEO Approval Rating

82/100

OVERVIEW

Founded:

1989

Headquarters:

CarlsbadCalifornia

Status:

PublicIndependent Company of NASDAQIONS

Industry Sector:

Pharmaceuticals

Biotechnology

SIC Code:

2834NAICS listing »

2836NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Regulus a competitor of Ionis?

I don't know

Trending News for Ionis and Ionis's Competitors

December 11, 2019

DirectorsTalk Interviews

Ionis Pharmaceuticals, Inc. - Consenus Indicates Potential 8.2% Upside

Ionis Pharmaceuticals, Inc. with ticker code (IONS) have now 16 analysts covering the stock with the ... See more »

December 11, 2019

MarketScreener

Arrowhead Pharmaceuticals : Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

(marketscreener.com) Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submit... See more »

December 12, 2019

DirectorsTalk Interviews

Alnylam Pharmaceuticals, Inc. - Consenus Indicates Potential 3.5% Upside

Alnylam Pharmaceuticals, Inc. found using ticker (ALNY) have now 20 analysts in total covering the st... See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

Alnylam is one of Ionis's top competitors. Alnylam was founded in 2002, and its headquarters is in Cambridge, Massachusetts. Like Ionis, Alnylam also works within the Pharmaceuticals sector. Alnylam has 328 more employees than Ionis.

Arrowhead is Ionis's #2 rival. Arrowhead was founded in 1989 in Pasadena, California. Arrowhead operates in the Biotechnology industry. Arrowhead generates $652.2M less revenue than Ionis.

OncoGenex is a top competitor of Ionis. OncoGenex is a Public company that was founded in Bothell, Washington in 2000. OncoGenex is in the Pharmaceuticals field. OncoGenex has 724 fewer employees vs. Ionis.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

Stanley T. Crooke

Chairman & CEO

- -
737
$267.3M
$821M
1

John Maraganore

CEO

90/100
1,065
$417.5M
$169.1M
2

Christopher Anzalone

President & CEO

81/100
113
$170.6M
$168.8M
3

Scott Cormack

President & CEO

70/100
13
$21.5M
$14.3M
4

Joseph P Hagan

President & CEO

85/100
97
$191.5M
$6.8M
5

Andre Turenne

President & CEO

89/100
77
$205M
$73.7M
6

Neil Kumar

CEO

86/100
24
$170.3M
$26.7M
7

Angie You

CEO

83/100
50
- -
$1.2M
8

Douglas Treco

President & CEO

85/100
46
$48.2M
$5.5M
9

Jacqualyn Fouse

CEO

88/100
287
$193M
$96.5M
10

David R. Parkinson

President & CEO

86/100
15
$104M
$8.8M
The top 10 competitors in Ionis' competitive set are Alnylam, Arrowhead, OncoGenex, Regulus, Voyager Therapeutics, Eidos Therapeutics, Amunix, Ra Pharma, Agios and ESSA. Together they have raised over 1.5B between their estimated 2.0K employees. Ionis has 737 employees and is ranked 2nd among it's top 10 competitors. The top 10 competitors average 229.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$821M

Ionis's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 126.6M. Over the last four quarters, Ionis's revenue has decreased by 12.6%. Specifically, in Q3 2019's revenue was $167.9M; in Q2 2019, it was $163.8M; in Q1 2019, it was $297.2M; in Q4 2018, Ionis's revenue was $192.1M.

Acquisitions

No recent acquisitions found related to Ionis

Ionis Funding History

Since Ionis was founded in 1989, it has participated in 4 rounds of funding. In total Ionis has raised $267.2M. Ionis' last funding round was on Jul 2017 for a total of $10.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Jul 2017
$10M
Series A
Dec 2015
$5M
-
Debt
Aug 2012
$201.3M
-
Equity
Aug 2005
$51M
-

Total Funding: $267.3M

Since Ionis was founded in 1989, it has participated in 4 rounds of funding. In total Ionis has raised $267.2M. Ionis' last funding round was on Jul 2017 for a total of $10.0M

Investments

No recent investments found related to Ionis

Ionis News

November 8, 2019DirectorsTalk Interviews

Ionis Pharmaceuticals, Inc. - Consenus Indicates Potential 22.8% Upside

Ionis Pharmaceuticals, Inc. found using ticker (IONS) have now 15 analysts covering the stock. The an... See more »
November 6, 2019Seeking Alpha

Ionis up 4% premarket on profitable Q3, guidance boost

See more »
October 29, 2019Forbes

What Caused The Sell-Off In Ionis Pharmaceuticals Stock?

Ionis Pharmaceuticals (NASDAQ: IONS), a pharma company engaged in discovering and developing RNA-targ... See more »
October 28, 2019MarketScreener

Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference

(marketscreener.com) CARLSBAD, Calif., Oct. 28, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NAS... See more »
October 25, 2019Zacks

Ionis Pharmaceuticals Enters Oversold Territory

Ionis Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end ... See more »
October 23, 2019MarketScreener

Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences

(marketscreener.com) CARLSBAD, Calif., Oct. 23, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NAS... See more »
October 16, 2019Seeking Alpha

Ionis down 6% on delay of Huntington's disease data readout

See more »

Ionis Press Releases

August 7, 2019centralcharts

Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy

BOSTON, Mass. and CARLSBAD, Calif., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDA... See more »
May 7, 2019StreetInsider

New Long-Term TEGSEDI Safety and Efficacy Data Featured as an Oral Presentation at 2019 American Academy of Neurology Annual Meeting (AAN)

BOSTON and CARLSBAD, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA)... See more »
May 1, 2019PR Newswire

Positive clinical data at AAN 2019 reinforces Ionis' commitment to delivering life-changing medicines to patients with neurological diseases

CARLSBAD, Calif., May 1, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader ... See more »
March 7, 2019StreetInsider

Ionis Pharmaceuticals to Present at Upcoming Investor Conferences

CARLSBAD, Calif., March 7, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leade... See more »
February 25, 2019GlobeNewswire

AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License

Phase 3 planning and initiation activities underway... See more »
November 27, 2018centralcharts

First-in-class therapies using advanced antisense chemistries highlighted at 2018 American Society of Hematology Annual Meeting

CARLSBAD, Calif., Nov. 27, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leade... See more »
October 24, 2018centralcharts

Ionis Pharmaceuticals to Hold Third Quarter 2018 Financial Results Webcast

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesda... See more »

Headquarters

2855 Gazelle Court

Carlsbad, California92010

760-931-9200

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Ionis is a drug discovery company that engages in the development and commercialization of ribonucleic acid-targeted therapeutics. Ionis was founded in 1989. Ionis' headquarters is located in Carlsbad, California, USA 92010. It has raised 267.2M in 4 ...

CEO

Ionis's Chairman & CEO, Stanley T. Crooke, currently has an approval rating of 82%. Ionis's primary competitors are Alnylam, Arrowhead & OncoGenex.

Website

ionispharma.com

Frequently Asked Questions about Ionis

  1. When was Ionis founded?

    Ionis was founded in 1989

  2. Who is Ionis's CEO?

    Ionis's CEO is Stanley T. Crooke

  3. How much revenue does Ionis generate?

    Ionis generates $821M in revenue

  4. How much funding does Ionis have?

    Ionis has historically raised $267.3M in funding

  1. Where is Ionis's headquarters?

    Ionis's headquarters is in Carlsbad California, USA

  2. How many employees does Ionis have?

    Ionis has 737 employees

  3. What sector does Ionis operate in?

    Ionis is in Pharmaceuticals, Biotechnology

  4. Who are Ionis's competitors?

    Ionis's top competitors are Alnylam, Arrowhead, OncoGenex
Stay up-to-date with the latest news on Ionis